Discover why Abbott Laboratories (ABT) earns a buy rating with strong fundamentals, dividend growth, and growth prospects.
If you have been wondering whether Abbott Laboratories is still a buy at around $125 a share, you are not alone. This is exactly the kind of stock where valuation really matters. Despite slipping ...
San Diego police only provide the device to certified drug recognition experts, who say it’s a great tool, but also the last ...
Starbase has filed at least four lawsuits against the Texas Attorney General’s Office over its rulings that information ...
One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...
Abbott Laboratories (ABT), the global healthcare titan, announced on Dec. 22 that the U.S. Food and Drug Administration (FDA) ...
A handful of transformative transactions lifted 2025 merger and acquisitions totals, but dealmakers largely remained disciplined, prioritizing data-driven growth and digital platforms.
Applied BioCode, a leader in innovative molecular diagnostic solutions, announced today the submission of a new nucleic acid extraction claim for the KingFishertm Flex Nucleic Acid Purification System ...
Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...
On a snowy December afternoon, Brian O’Brien walked out of his final appointment with his doctor at the Mayo Clinic Health ...
On a snowy December afternoon, Brian O’Brien walked out of his final appointment with his doctor at the Mayo Clinic Health ...
Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results